"FOCUSED" FDA REFORM BILL COMBINED WITH ADMINISTRATIVE CHANGES ADVOCATED BY CDRH DIRECTOR BURLINGTON; DEVICE INDUSTRY SOFTENING POSITION ON LEGISLATION
This article was originally published in The Gray Sheet
Executive Summary
A consensus approach to FDA device program reform combining "focused" legislation with administrative changes should be jointly pursued by industry and the agency in the coming year, Bruce Burlington, director of FDA's Center for Devices and Radiological Health, said Dec. 10 at the Food and Drug Law Institute's annual educational conference in Washington, D.C.